Physician profile
Robert J Helm
NPI 1104887066
$1,447.51
in general payments reported to CMS, 2019-2025
30 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $122 · 2021: $17.11 · 2022: $28.10 · 2023: $147 · 2024: $323 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $210.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $142.54 | 2022-2025 | |
| Novo Nordisk INC | $130.20 | 2019-2024 | |
| Lilly USA, LLC | $100.30 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $98.51 | 2023-2025 | |
| Amgen INC. | $82.08 | 2019-2025 | Otezla, Repatha |
| Astellas Pharma US INC | $75.69 | 2019-2024 | Veozah |
| Boston Scientific Corporation | $74.75 | 2019-2021 | |
| Pfizer INC. | $70.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.52 | 2019 | |
| Exact Sciences Corporation | $46.18 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $34.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.92 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $29.72 | 2023 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.27 | 2025 | |
| Phathom Pharmaceuticals, INC. | $26.41 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $19.68 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $19.22 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $18.35 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.50 | 2020 | |
| Glaxosmithkline, LLC. | $15.36 | 2019 | |
| Inspire Medical Systems, INC. | $13.88 | 2025 | Inspire |
| Dexcom, INC. | $13.88 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $11.97 | 2020 | |
| Allergan, INC. | $11.86 | 2019 | |
| Merck Sharp & Dohme LLC | $11.17 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.